What is Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s (301246.SZ) StockRank?

MoatMap's StockRank for Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (301246.SZ) is 66/100, with a Buy signal. This is a composite score combining Quality (51), Value (26), and Momentum (77) factor ranks across MoatMap's 19,000+ stock universe.

Does Hubei Hongyuan Pharmaceutical Technology Co., Ltd. have an economic moat?

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (301246.SZ) has a Quality factor score of 51/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Hubei Hongyuan Pharmaceutical Technology Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (301246.SZ) is Buy, based on a StockRank of 66/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Hubei Hongyuan Pharmaceutical Technology Co., Ltd. in?

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (301246.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

301246.SZ

BUYREMOVE

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. · Healthcare · China · $1.9B · Avg Vol: $81M/d

StockRank

P/E (TTM)

42.1x

ROE

5.6%

D/E

0.1x

Dividend %

0.2%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Hubei Hongyuan Pharmaceutical operates primarily in commodity APIs and chemical intermediates rather than high-moat, validated biologics CDMO services, failing our quality and thematic thresholds.

COMPANY DESCRIPTION

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. operates a diversified business model spanning pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and lithium battery materials like lithium hexafluorophosphate (LiPF6). The company leverages its advanced chemical synthesis platforms to serve both the healthcare and green energy sectors. Its competitive advantage lies in its flexible manufacturing capabilities and strong cost control across multiple chemical product lines.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	305M	304M	262M	287M	-2.0%
EPS	0.18	0.03	0.02	0.04	-37.6%
Shares	353M	400M	400M	400M	+13.4%
Debt	64M	52M	55M	79M	7.0%
Equity	312M	644M	644M	659M	28.3%
Op CF	32M	5M	-2M	-27M	-83.6%
Inv CF	-55M	-306M	61M	-36M	—
Fin CF	43M	318M	-26M	34M	—

PRICE (1M)-13.6%

SMA 50SMA 200

$4.14

RSI (14)

32.2

52W High

$5.26

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

3.2%51.4

ROE

5.6%58.1

GP/Assets

8.0%23.1

Op. Margin

23.8%87.2

FCF/Assets

-1.1%46.7

Piotroski

—28.8

Int. Cover

11.6x66.6

D/E Ratio

0.13x61.5

Current Ratio

2.88x51.3

Value

P/E (TTM)

42.1x25.4

EV/EBITDA

20.9x17.4

P/FCF

—N/A

P/B

2.3x49.6

P/S

4.9x42.2

Div Yield

0.2%5.2

Momentum

52W High %

79%72.1

RS 6M

52%94.2

SMA 50/200

1.32x94.7

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

1524%98.1

FUNDAMENTALS

Market Cap

$1.9B

P/E (Forward)

—

Gross Margin

22.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 301246.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
301246.SZ	Hubei Hongyuan Pharmaceutical Technology Co., Ltd.(you)	$1.9B	66	BUY
603707.SS	Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.	$1.9B	65	BUY
002399.SZ	Shenzhen Hepalink Pharmaceutical Group Co., Ltd.	$2.2B	67	BUY
603858.SS	Shandong Buchang Pharmaceuticals Co., Ltd.	$2.3B	66	BUY
603456.SS	Zhejiang Jiuzhou Pharmaceutical Co., Ltd	$1.7B	62	HOLD
002550.SZ	Changzhou Qianhong Biopharma CO.,LTD	$1.2B	66	BUY
000756.SZ	Shandong Xinhua Pharmaceutical Company Limited	$1.4B	62	HOLD
300142.SZ	Walvax Biotechnology Co., Ltd.	$3.0B	67	BUY
002020.SZ	Zhejiang Jingxin Pharmaceutical Co., Ltd.	$1.7B	57	HOLD
601089.SS	Beijing Foyou Pharma CO.,LTD	$1.3B	61	HOLD

Peer medians: ROE 4.7% · P/E 27.6x · Gross margin 53.1%

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (301246.SZ) — Stock Score Summary

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (301246.SZ) has a MoatMap StockRank of 66/100 based on Quality (51/100), Value (26/100), and Momentum (77/100) factor scores. The current signal is BUY. Hubei Hongyuan Pharmaceutical operates primarily in commodity APIs and chemical intermediates rather than high-moat, validated biologics CDMO services, failing our quality and thematic thresholds.

Key Financial Metrics

Price	$4.14
Market Cap	$1.9B
P/E (TTM)	42.08
Price/Book	2.32
Return on Equity	5.6%
Return on Invested Capital	3.2%
Debt/Equity	13.05
Gross Margin	22.3%
Operating Margin	23.8%
Revenue Growth	62.3%
Dividend Yield	0.2%
Free Cash Flow	$-1M

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Hubei Hongyuan Pharmaceutical Technology Co., Ltd.’s (301246.SZ) StockRank?: MoatMap’s StockRank for Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (301246.SZ) is 66/100, with a Buy signal. It is a composite of Quality (51), Value (26), and Momentum (77) factor ranks across MoatMap’s 19,000+ stock universe.
Does Hubei Hongyuan Pharmaceutical Technology Co., Ltd. have an economic moat?: Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (301246.SZ) has a Quality factor score of 51/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Hubei Hongyuan Pharmaceutical Technology Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (301246.SZ) is Buy, based on a StockRank of 66/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Hubei Hongyuan Pharmaceutical Technology Co., Ltd. in?: Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (301246.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).